高敏时间分辨荧光免疫法检测PLA2R-IgG1及其在特发性膜性肾病预后中的临床应用
研究建立三步间接时间分辨荧光免疫法(TRFIA)检测PLA2R-IgG1抗体,检测范围0.85-300RU/mL,批内精密度3.54-5.93%、批间4.39-9.36%,回收率101.77-108.04%。应用于56例PLA2R-IMN患者初始血清,PLA2R-IgG1水平区分缓解与非缓解组优于PLA2R-IgG。
要点
- PLA2R-IgG1-TRFIA检测范围0.85-300RU/mL,精密度与回收率符合方法学要求。
- PLA2R-IgG1水平>2.21RU/mL提示PLA2R-IMN。
- PLA2R-IgG1区分缓解与非缓解组优于PLA2R-IgG(P=0.001 vs P=0.094)。
核心结论
- 首次建立定量检测PLA2R-IgG1的TRFIA方法,在预测IMN预后方面较PLA2R-IgG水平更具临床价值。
研究设计与样本
- 研究建立三步间接TRFIA法,以PLA2R抗原包被微孔板捕获PLA2R-IgG抗体,再用鼠抗人IgG1和Eu3+标记羊抗鼠IgG抗体检测。
- 方法应用于56例PLA2R-IMN患者的初始血清,分析PLA2R-IgG1抗体水平对IMN预后的预测价值。
主要发现
- PLA2R-IgG1-TRFIA检测范围为0.85-300RU/mL,批内精密度3.54-5.93%,批间精密度4.39-9.36%,回收率101.77-108.04%。
- PLA2R-IgG1水平>2.21RU/mL提示PLA2R-IMN。
- 初始诊断时,缓解组PLA2R-IgG中位水平为51.24RU/mL,非缓解组为93.27RU/mL。
- 非缓解组PLA2R-IgG1中位水平为603.32RU/mL,是缓解组(140.67RU/mL)的4.29倍。
- PLA2R-IgG1水平区分缓解与非缓解组(P=0.001)较PLA2R-IgG水平(P=0.094)更有效。
关键数值与推荐
- PLA2R-IgG1-TRFIA检测范围0.85-300RU/mL,批内精密度3.54-5.93%,批间精密度4.39-9.36%,回收率101.77-108.04%。
- PLA2R-IgG1水平>2.21RU/mL提示PLA2R-IMN。
- 初始诊断时缓解组PLA2R-IgG中位51.24RU/mL,非缓解组93.27RU/mL;非缓解组PLA2R-IgG1中位603.32RU/mL,为缓解组140.67RU/mL的4.29倍。
- PLA2R-IgG1区分缓解与非缓解组P=0.001,PLA2R-IgG的P=0.094。
临床怎么用
- 可采用PLA2R-IgG1-TRFIA检测PLA2R-IgG1抗体,辅助预测PLA2R-IMN患者的预后。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The objective of this study was to develop a highly sensitive time-resolved fluorescence immunoassay (TRFIA) method to detect phospholipase A2 receptor (PLA2R)-IgG1 antibodies and evaluate its clinical relevance in predicting the prognosis of individuals with idiopathic membranous nephropathy (IMN). MATERIALS AND METHODS: A three-step indirect TRFIA method was established using a PLA2R antigen-coated microtiter plate to capture PLA2R-IgG antibodies, followed by detection using mouse anti-human IgG1 and Eu3+-labeled goat anti-mouse IgG antibodies. This method was applied to the initial serum of 56 patients with PLA2R-IMN to investigate the clinical value of PLA2R-IgG1 antibody levels in predicting IMN prognosis. RESULTS: The detection range of PLA2R-IgG1-TRFIA was 0.85-300RU/mL, with intra-assay precision of 3.54-5.93 % and inter-assay precision of 4.39-9.36 %. Recoveries were 101.77-108.04 %. A PLA2R-IgG1 level above 2.21RU/mL indicated PLA2R-IMN. At initial diagnosis, the median PLA2R-IgG level was 51.24RU/mL in the remission group and 93.27RU/mL in the non-remission group. The median PLA2R-IgG1 level was 603.32RU/mL in the non-remission group, which was 4.29 times higher than that in the remission group (140.67RU/mL). PLA2R-IgG1 levels (P = 0.001) more effectively distinguished between remission and non-remission groups compared with PLA2R-IgG levels (P = 0.094). CONCLUSIONS: The first quantitative TRFIA for PLA2R-IgG1 was established, showing greater clinical value in predicting IMN prognosis, compared to that for PLA2R-IgG levels.
引用
- Gao S, Yu Y, Kao S, et al. Establishment of a high-sensitivity time-resolved fluorescence immunoassay with PLA2R-IgG1 antibody and its clinical application in idiopathic membranous nephropathy prognosis. Clin Chim Acta. 2024. PMID: 39491764. doi:10.1016/j.cca.2024.120019
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。